895 studies found for:    FDG
Show Display Options
Rank Status Study
1 Not yet recruiting Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia
Condition: Adrenal Gland Neoplasms
Interventions: Other: FDG positron emission tomography;   Other: Iodometomidate imaging
2 Terminated Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
Conditions: Lung Cancer;   SCLC;   NSCLC
Intervention: Other: 18F-deoxyglucose (FDG)
3 Completed FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Conditions: Malignant Pleural Effusion;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: carboplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel;   Procedure: computed tomography;   Procedure: positron emission tomography;   Radiation: fludeoxyglucose F 18;   Other: imaging biomarker analysis
4 Not yet recruiting Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery
Condition: Rectal Neoplasms
Interventions: Radiation: fludeoxyglucose F 18;   Device: positron emission tomography;   Device: magnetic resonance imaging;   Other: laboratory biomarker analysis
5 Unknown  A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
Condition: Glioblastoma
Intervention: Procedure: FDG-PET
6 Not yet recruiting 18F-deoxyglucose (FDG) PET-CMD
Condition: Patients With Idiopathic Dilated Cardiomyopathy
Intervention: Drug: 18F-deoxyglucose (FDG)
7 Completed
Has Results
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Condition: Non-Small Cell Lung Cancer
Interventions: Other: 2-deoxy-2-[18F]fluoro-D-glucose (FDG);   Other: 3'-deoxy-3'-[18F]fluorothymidine (FLT);   Drug: erlotinib HCl
8 Active, not recruiting Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules
Condition: Thyroid Neoplasms
Intervention: Other: FDG-PET Scan
9 Recruiting 18F-FDG PET/CT for IgG4-Related Disease
Condition: Autoimmune Disease
Intervention: Drug: 18F-FDG
10 Completed Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.
Condition: Ovarian Cancer
Intervention: Procedure: 1: FDG PET
11 Active, not recruiting Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: PET/CT scan;   Drug: 18F-FDG Injection;   Procedure: Preoperative 18F-FDG PET/CT Scan;   Drug: 18F-FDG for patients with Bladder Cancer;   Procedure: Surgical Procedure;   Procedure: Specimen PET/CT Scan
12 Unknown  Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.
Condition: Head and Neck Cancer
Intervention: Other: CT-FDG/PET scan of the head-and-neck region
13 Completed Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Conditions: Kidney Neoplasms;   Carcinoma, Renal Cell;   Kidney (Renal Cell) Cancer
Interventions: Procedure: FDG PET CT;   Procedure: DCE MRI;   Drug: F-18 Fluoro-deoxi-glucose;   Drug: Gadolinium-DTPA;   Drug: Sunitinib
14 Recruiting 11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
Condition: Pulmonary Hypertension
Interventions: Drug: 11C-acetate;   Drug: [18F]Fluoro-2-deoxy-2-D-glucose;   Other: Cardiac MRI
15 Withdrawn Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
Condition: Stage IIIA Non-small Cell Lung Cancer
Interventions: Procedure: positron emission tomography/computed tomography (PET/CT);   Radiation: fludeoxyglucose F 18
16 Completed FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis
Condition: Cholecystitis
Intervention: Drug: 18FDG (an FDA-approved radiopharmaceutical)
17 Not yet recruiting To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Liver Disease
Interventions: Drug: 18F- fluorocholine;   Drug: 18F- fluorodeoxyglucose
18 Recruiting MRI FDG PET Imaging Cervix
Condition: Cervical Cancer Squamous Cell
Intervention: Biological: 18-FDG PET/CT, DWI, DCE-MRI
19 Recruiting Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy
Condition: Squamous-cell Cervical Carcinoma Stage IB2 to IIB Without Spread to Lymph Nodes or Metastasis
Intervention: Device: 18F-FDG-PET
20 Completed Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated Venothromboembolism
Condition: Venothromboembolism
Intervention: Procedure: FDG-PET/CT

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years